SOURCE: Biogenerics Limited

July 06, 2007 16:00 ET

Biogenerics Limited Announces Official Name Change to Diversified Oil & Gas

TYLER, TX--(Marketwire - July 6, 2007) - Biogenerics Limited (PINKSHEETS: BIGN) (FRANKFURT: D9G) is pleased to announce that its name has been officially changed to Diversified Oil and Gas Holdings, Limited. The name change will be effective as of July 9, 2007. In conjunction with this, the company's securities have been assigned a new cusip number which is 25531 T 10 1. Also effective July 9, 2007, the company's new trading symbol is DVFI. The market symbol in Germany will remain as D9G. The Company is in the process of constructing a new website and will announce details on our existing website

James Lancaster, CEO, remarked, "This is the beginning of a new era for the company. The new name identifies the company in the oil and gas industry and the company continues its endeavors to complete all previously announced transactions."

About Biogenerics Limited

Biogenerics is a diversified investment venture capital firm focused on exploiting and distributing domestic oil and gas reserves. Biogenerics also has joint venture activities with Tyche Energy Inc and Hydroslotter Corp.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

Contact Information

  • Contact:

    James Lancaster
    Biogenerics Limited
    Corporate Inquiries (903)-581-4053
    Investor Relations inquire at